What Happened?
A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years.
Healthcare companies, drug makers, hospitals, and insurers, earn revenue from clinical services and product sales. While the sector is traditionally defensive, the hot PPI print creates a two-pronged headwind.
First, rising service-sector inflation (up 1.2% monthly) increases the operating costs for hospital systems and providers. Second, as inflation becomes a dominant political issue, drug companies' visible price-setting power makes them a primary target for regulatory intervention.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Drug Development Inputs & Services company Repligen (NASDAQ: RGEN) fell 3.2%. Is now the time to buy Repligen? Access our full analysis report here, it’s free.
- Senior Health, Home Health & Hospice company AdaptHealth (NASDAQ: AHCO) fell 3.6%. Is now the time to buy AdaptHealth? Access our full analysis report here, it’s free.
- Drug Development Inputs & Services company IQVIA (NYSE: IQV) fell 3.6%. Is now the time to buy IQVIA? Access our full analysis report here, it’s free.
Zooming In On IQVIA (IQV)
IQVIA’s shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 8 days ago when the stock gained 8.4% on the news that it reported strong first-quarter 2026 financial results that surpassed Wall Street expectations and raised its full-year earnings forecast.
The company announced revenue of $4.15 billion, an 8.4% increase compared to the same period in the previous year, with its adjusted earnings per share coming in at $2.90, both of which were above analyst forecasts.
Looking ahead, IQVIA showed confidence by reaffirming its full-year revenue guidance and increasing its outlook for adjusted earnings per share to a new range of $12.65 to $12.95.
IQVIA is down 23.3% since the beginning of the year, and at $172.94 per share, it is trading 29.2% below its 52-week high of $244.29 from January 2026. Investors who bought $1,000 worth of IQVIA’s shares 5 years ago would now be looking at only $753.00.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
